These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20339781)

  • 1. Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer.
    Saad ED; Reis PT; Borghesi G; Machado MC; Simon SD; Tabacof J; Gansl RC
    Rev Assoc Med Bras (1992); 2010; 56(1):22-6. PubMed ID: 20339781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
    Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
    J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
    Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
    Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
    Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
    Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
    Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
    Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
    Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
    Boeck S; Haas M; Laubender RP; Kullmann F; Klose C; Bruns CJ; Wilkowski R; Stieber P; Holdenrieder S; Buchner H; Mansmann U; Heinemann V
    Clin Cancer Res; 2010 Feb; 16(3):986-94. PubMed ID: 20103662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
    Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
    Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated preoperative levels of CA 19-9 and CA 125 predicts overall survival time in the pancreatic adenocarcinoma. Single institution series.
    Hogendorf P; Skulimowski A; Durczyński A; Kumor A; Poznańska G; Poznańska A; Oleśna A; Rut J; Øvereng Juliebø S; Szmiel A; Strzelczyk J
    Pol Przegl Chir; 2020 Apr; 92(3):32-38. PubMed ID: 32759395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy.
    Katz A; Hanlon A; Lanciano R; Hoffman J; Coia L
    Int J Radiat Oncol Biol Phys; 1998 May; 41(2):393-6. PubMed ID: 9607356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer.
    Peixoto RD; Speers C; McGahan CE; Renouf DJ; Schaeffer DF; Kennecke HF
    Cancer Med; 2015 Aug; 4(8):1171-7. PubMed ID: 25891650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
    Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
    J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
    Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
    Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
    Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.
    Kou T; Kanai M; Yamamoto M; Xue P; Mori Y; Kudo Y; Kurita A; Uza N; Kodama Y; Asada M; Kawaguchi M; Masui T; Mizumoto M; Yazumi S; Matsumoto S; Takaori K; Morita S; Muto M; Uemoto S; Chiba T
    Int J Clin Oncol; 2016 Feb; 21(1):118-25. PubMed ID: 26123314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
    Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
    J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer.
    Yang SH; Guo JC; Yeh KH; Tien YW; Cheng AL; Kuo SH
    J Gastroenterol Hepatol; 2016 Dec; 31(12):2004-2012. PubMed ID: 27059987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
    Micke O; Bruns F; Kurowski R; Horst E; deVries AF; Hausler JW; Willich N; Schäfer U
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):90-7. PubMed ID: 12909220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
    Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
    Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.